beta Carotene (CID 5280489) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(11)
 
 
Inactive(282)
 
 
Inconclusive(30)
 
 
Unspecified(180)
 
 
Top Targets:
TRP 2(5)
 
 
HCV capsid(5)
 
 
 
alkPPc(4)
 
 
KCNQ channel(4)
 
 
CASc(3)
 
 
BioAssay Types:
Literature(234)
 
 
 
 
 
Screening(128)
 
 
 
 
Confirmatory(91)
 
 
 
 
BioActivity Types:
Potency(73)
 
 
 
 
IC50(14)
 
 
 
EC50(2)
 
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 442    Data Row: 503   Total Pages: 11   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103401011]
IC50 0.0127Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs [AID288764, Type: Literature]
View
2
[SID103401011]
EC50 6.3Antiviral activity against HCV assessed as inhibition of HCV RNA replication in OR6 cells after 72 hrs by luciferase reporter assay [AID323922, Type: Literature]
View
3
[SID103401011]
IC50 16.9Antioxidant activity assessed as hydrogen peroxide scavenging activity by peroxyoxalate chemiluminescent method [AID452853, Type: Literature]
View
4
[SID48413385]
 DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity [AID1194, Type: other]
View
5
[SID47193664]
 Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity [AID504408, Type: screening]
View
6
[SID47193664]
 TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization [AID1899, Type: screening]core protein [Hepatitis C virus] [gi:83779224]
View
7
[SID103401011]
 Antiviral activity against HCV assessed as suppression of HCV RNA replication in ORN/C-5B/KE/poly cells after 72 hrs by luciferase reporter assay [AID323924, Type: Literature]
View
8
[SID103401011]
 Antiviral activity against HCV assessed as suppression of HCV RNA replication in ORN/3-5B/KE/poly cells after 72 hrs by luciferase reporter assay [AID323925, Type: Literature]
View
9
[SID103401011]
 Antiviral activity against HCV assessed as inhibition of HCV RNA replication in OR6 cells after 24 hrs by luciferase reporter assay [AID323928, Type: Literature]
View
10
[SID103401011]
 Antiradical activity assessed as DPPH radical scavenging activity at 1050 uM by spectrophotometry relative to control [AID378050, Type: Literature]
View
11
[SID48415624]
 DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
12
[SID103401011]
 Cytotoxicity against human OR6 cells after 120 hrs by cell viability assay [AID323923, Type: Literature]
View
13
[SID26750098]
Potency qHTS Assay for Activators of Cytochrome P450 3A4 [AID885, Type: confirmatory]cytochrome P450, family 3, subfamily A, polypeptide 4 [Homo sapiens] [gi:13435386]
View
14
[SID26750098]
Potency qHTS Assay for Activators of Cytochrome P450 3A4 [AID885, Type: confirmatory]cytochrome P450, family 3, subfamily A, polypeptide 4 [Homo sapiens] [gi:13435386]
View
15
[SID26750098]
Potency qHTS Assay for Activators of Cytochrome P450 3A4 [AID885, Type: confirmatory]cytochrome P450, family 3, subfamily A, polypeptide 4 [Homo sapiens] [gi:13435386]
View
16
[SID103401011]
 Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio relative to TPA [AID379565, Type: Literature]
View
17
[SID103401011]
 Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio relative to TPA [AID379566, Type: Literature]
View
18
[SID103401011]
 Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio relative to TPA [AID379567, Type: Literature]
View
19
[SID103401011]
 Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio relative to TPA [AID379568, Type: Literature]
View
20
[SID103401011]
 Inhibition of TPA-induced EBV-early antigen activation in human Raji cells relative to TPA [AID379569, Type: Literature]
View
21
[SID103401011]
 Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio [AID379570, Type: Literature]
View
22
[SID103401011]
 Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio [AID379571, Type: Literature]
View
23
[SID103401011]
 Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio [AID379572, Type: Literature]
View
24
[SID103401011]
 Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio [AID379573, Type: Literature]
View
25
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 1000 mol ratio relative to TPA [AID381367, Type: Literature]
View
26
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 500 mol ratio relative to TPA [AID381368, Type: Literature]
View
27
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 100 mol ratio relative to TPA [AID381369, Type: Literature]
View
28
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 10 mol ratio relative to TPA [AID381370, Type: Literature]
View
29
[SID103401011]
 Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio/TPA [AID381371, Type: Literature]
View
30
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 1000 mol ratio relative to TPA [AID398024, Type: Literature]
View
31
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 500 mol ratio relative to TPA [AID398025, Type: Literature]
View
32
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 100 mol ratio relative to TPA [AID398026, Type: Literature]
View
33
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced Epstein-Barr virus early antigen activation in human Raji cells assessed as EA induction at 10 mol ratio relative to TPA [AID398027, Type: Literature]
View
34
[SID103401011]
 Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio after 48 hours relative to TPA [AID398028, Type: Literature]
View
35
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 1000 molar ratio after 48 hrs relative to TPA [AID400253, Type: Literature]
View
36
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 500 molar ratio after 48 hrs relative to TPA [AID400254, Type: Literature]
View
37
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 100 molar ratio after 48 hrs relative to TPA [AID400255, Type: Literature]
View
38
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 10 molar ratio after 48 hrs relative to TPA [AID400256, Type: Literature]
View
39
[SID103401011]
 Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio by trypan blue assay [AID400257, Type: Literature]
View
40
[SID103401011]
 Inhibition of TPA-induced Epstein-Barr virus early antigen activation in human Raji cells at 1000 molar ratio relative to TPA [AID400339, Type: Literature]
View
41
[SID103401011]
 Inhibition of TPA-induced Epstein-Barr virus early antigen activation in human Raji cells at 500 molar ratio relative to TPA [AID400340, Type: Literature]
View
42
[SID103401011]
 Inhibition of TPA-induced Epstein-Barr virus early antigen activation in human Raji cells at 100 molar ratio relative to TPA [AID400341, Type: Literature]
View
43
[SID103401011]
 Inhibition of TPA-induced Epstein-Barr virus early antigen activation in human Raji cells at 10 molar ratio relative to TPA [AID400342, Type: Literature]
View
44
[SID103401011]
 Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio [AID400343, Type: Literature]
View
45
[SID103401011]
 Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio [AID400344, Type: Literature]
View
46
[SID103401011]
 Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio [AID400345, Type: Literature]
View
47
[SID103401011]
 Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio [AID400346, Type: Literature]
View
48
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 1000 molar ratio per 32 pmol/ml TPA by immunofluorescence technique relative to control [AID400777, Type: Literature]
View
49
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 500 molar ratio per 32 pmol/ml TPA by immunofluorescence technique relative to control [AID400778, Type: Literature]
View
50
[SID103401011]
 Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 100 molar ratio per 32 pmol/ml TPA by immunofluorescence technique relative to control [AID400779, Type: Literature]
View